Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Erstveröffentlichung
2009
Beitrag zu einer Konferenz
Published in
Journal of Clinical Oncology ; 27 (2009), 24. - S. 3994-4001. - ISSN 0732-183X
Link to publication
https://dx.doi.org/10.1200/JCO.2008.21.1128Institutions
UKU. Klinik für Innere Medizin IIIConference
50th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA, DEC 06-09, 2008, 2008-12-06 - 2008-12-09, San Francisco, CA
Subject headings
[Free subject headings]: stem-cell transplantation | phase-3 trial | term-follow-up | plus cyclophosphamide | 1st-line therapy | high-risk | genomic aberrations | survival | p53 | efficacy[DDC subject group]: DDC 610 / Medicine & health